Do We Initiate Chemotherapy at an Early Stage of Hormone-Sensitive Metastatic Prostate Cancer?

被引：0
|
作者：
Nayir, Erdinc [1 ]
Keskin, Ozge [2 ]
机构：
[1] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkey
[2] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkey
来源：
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2016年 / 31卷 / 04期
关键词：
D O I：
10.5505/tjo.2016.1478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [21] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Arnold Lee
    Targeted Oncology, 2023, 18 : 793 - 800
  • [22] Optimal treatment for metastatic hormone-sensitive prostate cancer
    Omlin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
  • [23] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
  • [24] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
    Li, Hengping
    Zhang, Mao
    Wang, Xiangrong
    Liu, Yang
    Li, Xuanpeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [26] Systemic therapy in metastatic hormone-sensitive prostate cancer
    McDonald, Jodie
    O'Brien, Jonathan
    Kostos, Louise
    Lawrentschuk, Nathan
    Azad, Arun A.
    Murphy, Declan
    Chen, Kenneth
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2022, 16 (04) : 234 - 239
  • [27] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [28] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Montesa-Pino, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe
    Tammela, Teuvo L. J.
    Suzuki, Hiroyoshi
    Utriainen, Tapio
    Fu, Cheng
    Uemura, Motohide
    Mendez-Vidal, Maria J.
    Maughan, Benjamin L.
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
  • [29] Treatment of primary cancer in metastatic hormone-sensitive prostate cancer
    Lim, Kylie Y. -Y.
    Alberto, Matthew
    Ranasinghe, Weranja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (04) : 315 - 323
  • [30] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
    Kwan, Edmond M.
    Azad, Arun A.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 617 - 619
12345